Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 538

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 538
---
1/2 study. Under the terms of the agreement, Mirati was responsible for sponsoring and operating the Phase 1/2 study and the Company supplied study drug and jointly shared the cost of the
study, which will continue during the winding down process.

F-56

For the three and nine months ended September 30, 2024, the Company incurred $0.3 million and
$1.0 million in expenses related to the Mirati collaboration. For the three and nine months ended September 30, 2023, the Company incurred $0.1 million and $0.7 million in expenses related to the Mirati collaboration.

13. Restructuring

On August 21, 2024, the Company
announced a restructuring plan to reduce the Company’s workforce by approximately 32% in response to the Company’s announcement on August 20, 2024 that it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The Company recorded a total restructuring charge of $2.6 million, which consists of one-time termination benefits such as severance costs and related benefits. For the three and nine months ended September 30, 2024, the Company made cash payments related to the restructuring of
$0.4 million. As of September 30, 2024, the $2.2 million one-time termination benefits remain payable and are recorded within the accrued expenses and other liabilities line item on the
Company’s condensed balance sheet. Restructuring payments commenced in September 2024 and will extend through December 2024.

F-57

Annex A

STOCK PURCHASE AGREEMENT

among

KAKEN PHARMACEUTICAL CO., LTD.

KAKEN INVESTMENTS INC.,

AADI BIOSCIENCE, INC.

and

AADI SUBSIDIARY, INC.

Dated as of December 19, 2024

TABLE OF CONTENTS

|                                                        |     |                                                              |     | Page |      |
| ARTICLE I DEFINITIONS & INTERPRETATIONS                |     |                                                              |     |      | A-2  |
| 1.1                                                    |     | Certain Definitions                                          |     |      | A-2  |
| 1.2                                                    |     | Additional Definitions                                       |     |      | A-17 |
| 1.3                                                    |     | Certain Interpretations                                      |